L.R.A. triennial index digest, 1915-1917 combining notes and cases in one alphabetical arrangement, and supplementing digests 1-70 L.R.A. and 1-52 L.R.A. (N.S.) and indexes to notes 1 L.R.A.-42 L.R.A. (N.S.) and 43 L.R.A. (N.S.)-L.R.R. 1916 F.

Mode of access: Internet.

Hydrology of area 52, Rocky Mountain coal province Wyoming, Colorado, Idaho, and Utah /

Mode of access: Internet.

Konzert für Violine und Orchester : op. 52 /

For violin and piano.

Fragm. lat. III 52 - Theologischer Text

Trägerband: Ms. Praed. 111; Vorbesitzer: Dominikanerkloster Frankfurt am Main

Fragm. lat. IX 18 - Digesta (28.5.45 - 52; 32.1.3 - 11)

Trägerbände: Inc. fol. 170 Bd. 3; Inc. fol. 170 Bd. 4; Vorbesitzer: Bartholomaeusstift Frankfurt am Main

Fragm. lat. I 52 - Missale (Paulus ap.)

Vorbesitzer: Dominikanerkloster Frankfurt am Main

Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry

The Australian Pregnancy Registry, affiliated European Register of Antiepileptic drugs in Pregnancy (EURAP), recruits informed consenting women with epilepsy on treatment with antiepileptic drugs (AEDs), those untreated, and women on AEDs for other indications. Enrolment is considered prospective if it has occurred before presence or absence of major foetal malformations (FMs) are known, or retrospective, if they had occurred after the birth of infant or detection of major FM. Telephone Interviews are conducted to ascertain pregnancy outcome and collect data about seizures. To date 630 women have been enrolled, with 565 known pregnancy outcomes. Valproate (VPA) above 1100 mg/day was associated with a significantly higher incidence of FMs than other AEDs (P < 0.05). This was independent of other AED use or potentially confounding factors on multivariate analysis (OR = 7.3, P < 0.0001). Lamotrigine (LTG) monotherapy (n = 65), has so far been free of malformations. Although seizure control was not a primary outcome, we noted that more patients on LTG than on VPA required dose adjustments to control seizures. Data indicate an increased risk of FM in women taking VPA in doses > 1100 mg/day compared with other AEDs. The choice of AED for pregnant women with epilepsy requires assessment of balance of risks between teratogenicity and seizure control.

Wonder Down Under: Australian sci-fi 1948-52

Moral guardians, industry protectionists and concerned citizens (each with their own political agendas) had, or many years, lobbied various Ministers of Customs to regulate the offensive material which flooded the local market-the war effectively opened a protectionist climate in which the local publishing industry nourished (Johnson-Woods Pulp Friction). Though westerns dominated at first, science fiction (i.e., futuristic stories, alternative histories, space exploration, time-travel past and future ) soon followed. Within the decaying and yellowed pages, contemporary readers have a glimpse into the culture of the 1950s and, amusing though some of the predictions are, the cultural and social critic gains some understanding of the anxieties and desires of post-World War II Australia.

CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors:a comparison of effects of adrenomedullin 22-52, CGRP 8-37 and BIBN4096BS

1. Adrenomedullin (AM) has two known receptors formed by the calcitonin receptor-like receptor (CL) and receptor activity-modifying protein (RAMP) 2 or 3: We report the effects of the antagonist fragments of human AM and CGRP (AM 22-52 and CGRP 8-37) in inhibiting AM at human (h), rat (r) and mixed species CL/RAMP2 and CL/RAMP3 receptors transiently expressed in Cos 7 cells or endogenously expressed as rCL/rRAMP2 complexes by Rat 2 and L6 cells. 2. AM 22-52 (10 μM) antagonised AM at all CL/RAMP2 complexes (apparent pA 2 values: 7.34±0.14 (hCL/hRAMP2), 7.28±0.06 (Rat2), 7.00±0.05 (L6), 6.25±0.17(rCL/hRAMP2)). CGRP 8-37 (10 μM) resembled AM 22-52 except on the rCL/hRAMP2 complex, where it did not antagonise AM (apparent PA 2 values: 7.04±0.13 (hCL/hRAMP2), 6.72±0.06 (Rat2), 7.03±0. 12 (L6)). 3. On CL/RAMP3 receptors, 10 μM CGRP 8-37 was an effective antagonist at all combinations (apparent pA 2 values: 6.96±0.08 (hCL/hRAMP3), 6.18±0.18 (rCL/rRAMP3), 6.48±0.20 (rCL/ hRAMP3)). However, 10 μm AM 22-52 only antagonised AM at the hCL/hRAMP3 receptor (apparent PA 2 6.73±0.14). 4. BIBN4096BS (10 μM) did not antagonise AM at any of the receptors. 5. Where investigated (all-rat and rat/human combinations), the agonist potency order on the CL/ RAMP3 receptor was AM∼βCGRP>αCGRP. 6. rRAMP3 showed three apparent polymorphisms, none of which altered its coding sequence. 7. This study shows that on CL/RAMP complexes, AM 22-52 has significant selectivity for the CL/ RAMP2 combination over the CL/RAMP3 combination. On the mixed species receptor, CGRP 8-37 showed the opposite selectivity. Thus, depending on the species, it is possible to discriminate pharmacologically between CL/RAMP2 and CL/RAMP3 AM receptors.